Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 1309Neoplasms 1103Carcinoma, Non-Small-Cell Lung 905Prostatic Neoplasms 739Colorectal Neoplasms 628Lung Neoplasms 617Neoplasm Metastasis 466Multiple Myeloma 447Leukemia, Myeloid, Acute 437Pancreatic Neoplasms 387Ovarian Neoplasms 383Melanoma 341Carcinoma, Hepatocellular 306Brain Neoplasms 292Recurrence 284Squamous Cell Carcinoma of Head and Neck 282Glioblastoma 254Head and Neck Neoplasms 250Stomach Neoplasms 248Precursor Cell Lymphoblastic Leukemia-Lymphoma 237Lymphoma 236Carcinoma, Renal Cell 234Triple Negative Breast Neoplasms 233Hematologic Neoplasms 215Endometrial Neoplasms 214Urinary Bladder Neoplasms 212Uterine Cervical Neoplasms 209Glioma 201Lymphoma, Non-Hodgkin 199Sarcoma 196

Interventions

temsirolimus 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × 90 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡